ATGGF Stock Price, Chart, Stats & News

Actinogen Medical Limited
Save
Actinogen Medical Limited (ATGGF) does not currently pay a dividend.
223.05M
Market cap
–
Current P/E
–
Forward P/E
ATGGF chart
About
Health care
Sector
Biotechnology
Industry
Actinogen Medical Limited is an Australian biotechnology firm specializing in the creation of treatments for neurological and neuropsychiatric conditions linked to abnormal brain cortisol levels. Their primary therapeutic candidate, Xanamem, functions as an inhibitor of the 11ß-HSD1 enzyme. Currently in Phase 2 clinical trials, Xanamem has shown the ability to engage its intended target within the central nervous system.
Similar securities
Based on sector and market capitalization
Report issue





